BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tislelizumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tislelizumab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07829926-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07829926)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Lenvatinib Plus Tislelizumab Wi
 th or Without Gefitinib for Advanced Liver Cancer\nEstimated primary compl
 etion: November 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07829926
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03736889-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT03736889)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Tislelizumab (Anti-Programmed C
 ell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors\nEstima
 ted primary completion: November 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03736889
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06704620-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06704620)
DESCRIPTION:Tislelizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Re
 ceptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small
  Cell Lung Cancer\nEstimated primary completion: November 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06704620
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06725498-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06725498)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Intra-arterial Chemotherapy Com
 bined with Radiotherapy and Immunotherapy for HNSCC\nEstimated primary com
 pletion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06725498
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06749886-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06749886)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: An
  Exploratory Study of Tislelizumab in Combination with Chemotherapy in Imm
 uno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the
  Second-line Setting\nEstimated primary completion: 30 November 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06749886
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05238883-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT05238883)
DESCRIPTION:Tislelizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of HFB200301 as a Single Agent and in Combination With Tislelizumab 
 in Adult Patients With Advanced Solid Tumors\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisl
 elizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05238883
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05789069-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT05789069)
DESCRIPTION:Tislelizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of HFB200603 as a Single Agent and in Combination With Tislelizumab 
 in Adult Patients With Advanced Solid Tumors\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisl
 elizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05789069
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06538896-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06538896)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Tislelizumab Combined with Nab-
 Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Can
 cer with Bone Metastasis，an Exploratory\, Single-Arm\, Multicenter Phase
  II Clinical Study\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06538896
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000617-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07000617)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: A Phase II Study of Dexamethaso
 ne\, Azacitidine\, Pegaspargase and Tislelizumab Plus Radiotherapy for Pat
 ients With Stage I/II Extranodal NK/T-cell Lymphoma\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07000617
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06838910-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06838910)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Tislelizumab Combined With Anlo
 tinib as Second-line Therapy in Thymoma and Thymic Carcinoma\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06838910
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07512674-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07512674)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Modified Short-Course Radiother
 apy Combined With Immunochemotherapy and Targeted Therapy as First-Line Tr
 eatment for MSS Metastatic Colorectal Cancer\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisl
 elizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07512674
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05531123-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT05531123)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Risk-stratification Based Bladd
 er-sparing Modalities for Muscle-invasive Bladder Cancer\nEstimated primar
 y completion: December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05531123
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06177301-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06177301)
DESCRIPTION:Tislelizumab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Tisl
 elizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC\n
 Estimated primary completion: December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06177301
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535840-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase na readout est. (NCT07535840)
DESCRIPTION:Tislelizumab\, phase na.\nStudy: A Clinical Trial of Firsekibar
 t\, Tislelizumab\, and Lenvatinib in Patients With Unresectable\, TP53-Mut
 ated Hepatocellular Carcinoma\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07535840
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06499350-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT06499350)
DESCRIPTION:Tislelizumab\, phase 1/2.\nStudy: A Study of FC084CSA in Combin
 ation of Tislelizumab in Patients With Advanced Malignant Solid Tumors\nEs
 timated primary completion: 1 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06499350
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04615143-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT04615143)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Tislelizumab or Tislelizumab Co
 mbined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC\nEstimat
 ed primary completion: 1 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04615143
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06647680-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06647680)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Neoadjuvant Chemotherapy and PD
 -1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）\nEstimated
  primary completion: 1 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06647680
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312982-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Tislelizumab: Phase 2/3 readout est. (NCT06312982)
DESCRIPTION:Tislelizumab\, phase 2/3.\nStudy: A Series of Neoadjuvant Chemo
 radiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cance
 r\nEstimated primary completion: 1 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06312982
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768932-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT05768932)
DESCRIPTION:Tislelizumab\, phase 1\, Gastric Cancer.\nStudy: BAL0891 in Pat
 ients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid L
 eukemia\nEstimated primary completion: 24 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05768932
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05253118-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT05253118)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Relapsed or Refractory Primary 
 Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)\
 nEstimated primary completion: 28 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05253118
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06366945-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06366945)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Tirelizumab in Combination With
  Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in 
 cN+ HNSCC\nEstimated primary completion: 30 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06366945
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06664021-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06664021)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Exploring the Efficacy and Safe
 ty of Tislelizumab in Combination With S-1 in the Treatment of Patients Wi
 th Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma\nEsti
 mated primary completion: 30 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06664021
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07126119-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07126119)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Neoadjuvant Tislelizumab in Com
 bination With Nab-Paclitaxel for UTUC\nEstimated primary completion: 30 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisleliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07126119
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07233252-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07233252)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Nephron-sparing Treatment of Ti
 slelizumab + Nab-Paclitaxel for Renal Pelvic Cancer\nEstimated primary com
 pletion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07233252
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356597-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06356597)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Tislelizumab With Fruquintinib\
 , Metronidazole\, in Mismatch Repair-proficient or Microsatellite Stabilit
 y\, Advanced Colorectal Cancer: a Multicenter\, Single Arm\, Clinical Tria
 l\nEstimated primary completion: 30 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06356597
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05837806-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT05837806)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Efficacy and Safety of Tisleliz
 umab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2
 -positive High-risk Upper Tract Urothelial Carcinoma (UTUC)\nEstimated pri
 mary completion: 30 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05837806
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07413042-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT07413042)
DESCRIPTION:Tislelizumab\, phase 1\, Small Cell Lung Cancer.\nStudy: A Phas
 e I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOT
 ATATE Injection Combined With Tislelizumab in the Maintenance Treatment Pe
 riod for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With
  Somatostatin Receptors (SSTR)+ as First-line Treatment\nEstimated primary
  completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07413042
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238167-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06238167)
DESCRIPTION:Tislelizumab\, phase 2\, Gastric Cancer.\nStudy: Tislelizumab P
 lus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients Wit
 h LA GC/GEJC\nEstimated primary completion: 31 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06238167
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05477264-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT05477264)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Concurrent Tislelizumab and Rad
 iotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma\, Nasal Type\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05477264
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06430658-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06430658)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Neoadjuvant Comprehensive Treat
 ment for Unresectable Esophageal Cancer\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislel
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06430658
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06676722-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06676722)
DESCRIPTION:Tislelizumab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: SBRT
  Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent
 /Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06676722
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304258-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07304258)
DESCRIPTION:Tislelizumab\, phase 2\, Gastric Cancer.\nStudy: A Prospective\
 , Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Con
 version Therapy for Gastric Cancer With Peritoneal Metastasis With Positiv
 e Cytology Alone or PCI Score ≤10\nEstimated primary completion: 31 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7304258
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07330037-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07330037)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: TA
 LENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectab
 le NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy\nEstimated prima
 ry completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07330037
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05668884-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT05668884)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: GEMOX Combined With Donafenib a
 nd Tislelizumab in Advanced Biliary Tract Carcinoma\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05668884
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06536868-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06536868)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Tislel
 izumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06536868
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05823311-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT05823311)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Lenvatinib\, Tislelizumab Combi
 ned with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Ch
 olangiocarcinoma\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05823311
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06939439-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06939439)
DESCRIPTION:Tislelizumab\, phase 3\, Gastric Cancer.\nStudy: Using ctDNA to
  Guide Treatment Decisions for Stage III Gastric Cancer\nEstimated primary
  completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06939439
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04170283-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT04170283)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: A Study to Evaluate Long-term S
 afety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Wh
 o Participated in BeiGene Parent Studies of Zanubrutinib\nEstimated primar
 y completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04170283
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07025850-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT07025850)
DESCRIPTION:Tislelizumab\, phase 1/2.\nStudy: Efficacy Study of Digoxin Com
 bined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Adv
 anced Colorectal Cancer\nEstimated primary completion: 1 January 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07025850
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793228-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06793228)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Nanocr
 ystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia\nEstima
 ted primary completion: 15 January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06793228
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07320105-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Tislelizumab: Phase 4 readout est. (NCT07320105)
DESCRIPTION:Tislelizumab\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: Po
 stoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the I
 mmunotherapy Era (Phase II)\nEstimated primary completion: 15 January 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07320105
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04699188-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT04699188)
DESCRIPTION:Tislelizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS 
 G12C Mutation\nEstimated primary completion: 25 January 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04699188
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06851819-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06851819)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Tislel
 izumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stag
 e Oligometastatic Small Cell Lung Cancer.\nEstimated primary completion: 3
 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisle
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06851819
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07300891-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07300891)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: T Cell Inflamed Gene Expression
  Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for R
 efractory Solid Cancer Patients Unexposed to Immunotherapy\nEstimated prim
 ary completion: 31 January 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07300891
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07019675-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07019675)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: A Study of SKB518 in Patients W
 ith Lung Cancer\nEstimated primary completion: 20 February 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07019675
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05687357-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT05687357)
DESCRIPTION:Tislelizumab\, phase 2\, Gastric Cancer.\nStudy: Tislelizumab i
 n Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ
  Adenocarcinoma\nEstimated primary completion: 28 February 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05687357
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07348107-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT07348107)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: ATRA and SDK002 in Combination 
 With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancre
 atic Ductal Adenocarcinoma.\nEstimated primary completion: March 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07348107
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06838208-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06838208)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Tislel
 izumab Combined With Chemotherapy and Relayed Radiotherapy in First-line T
 reatment of ES-SCLC\nEstimated primary completion: 1 March 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06838208
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860477-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06860477)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Cryoablation Combined With Lenv
 atinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced In
 trahepatic Cholangiocarcinoma (CASTLE-ZS-01)\nEstimated primary completion
 : 15 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisl
 elizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06860477
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04387084-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT04387084)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: Short-term Fasting Prior to PD-
 1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy\nE
 stimated primary completion: 31 March 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04387084
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427941-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT06427941)
DESCRIPTION:Tislelizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Phase 1/2 Study of BGB-B2033\, Alone or in Combination With Tislelizumab
  With or Without Bevacizumab\, in Participants With Advanced or Metastatic
  Solid Tumors\nEstimated primary completion: 31 March 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06427941
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06978829-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06978829)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Cetuximab + Tislelizumab + Chem
 otherapy in the Treatment of Unresectable LA HNSCC\nEstimated primary comp
 letion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06978829
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07531979-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07531979)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Prospective\, Open-label\, Multi-cohort Study of Becotatug Vedotin W
 ith Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - 
 Phase 2\nEstimated primary completion: 31 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07531979
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07413354-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07413354)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Tislelizumab Combined With Huai
 er Granule as First-line Treatment for Unresectable Hepatocellular Carcino
 ma\nEstimated primary completion: 31 March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07413354
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104604-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07104604)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Study on the Efficacy and Safet
 y of Neoadjuvant Radiotherapy Combined With Tislelizumab\, Liposomal Irino
 tecan\, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal 
 Adenocarcinoma With Low Rectal Involvement\nEstimated primary completion: 
 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislel
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07104604
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06375109-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06375109)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: PD-L1/
 PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadj
 uvant Treatment of Limited-stage SCLC\nEstimated primary completion: 15 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 375109
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364904-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06364904)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: A Clinical Trail to Determine t
 he Safety and Efficacy of the Combination of Tislelizumab With Cisplatin a
 nd Gemcitabine\, With or Without Trilaciclib for Patients With Untreated U
 nresectable and Metastatic Urothelial Carcinoma.\nEstimated primary comple
 tion: 15 April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06364904
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06969612-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT06969612)
DESCRIPTION:Tislelizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizum
 ab and Chemotherapy as First-line Treatment for Advanced NSCLC\nEstimated 
 primary completion: May 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06969612
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07458529-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07458529)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Neoadjuvant Chemoradiotherapy P
 lus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Re
 ctal Cancer\nEstimated primary completion: 5 May 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07458529
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07565740-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT07565740)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: Intranasal WSK-IM05 Vaccine Plu
 s Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC\nEstimated primary co
 mpletion: 10 May 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07565740
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06383780-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06383780)
DESCRIPTION:Tislelizumab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Tisl
 elizumab in Combination With GP or TPC Regimen for the Treatment of Nasoph
 aryngeal Carcinoma With Bone Metastasis.\nEstimated primary completion: 15
  May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6383780
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05886439-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT05886439)
DESCRIPTION:Tislelizumab\, phase 1/2.\nStudy: LK101 Combined With PD-1 or P
 D-L1 Monoclonal Antibody in the Treatment of Lung Cancer\nEstimated primar
 y completion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05886439
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06354140-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06354140)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC
  After Radical Resection With Neoadjuvant STUDY\nEstimated primary complet
 ion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tis
 lelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06354140
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010120-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT07010120)
DESCRIPTION:Tislelizumab\, phase 1/2.\nStudy: A Clinical Trial of Neoadjuva
 nt Targeted Therapy\, Immunotherapy\, and Lysogenic HSV-Based Virotherapy 
 in Resectable Head and Neck Squamous Cell Carcinoma\nEstimated primary com
 pletion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07010120
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05978102-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT05978102)
DESCRIPTION:Tislelizumab\, phase 1/2.\nStudy: A Dose Escalation and Dose Ex
 pansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors\
 nEstimated primary completion: June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05978102
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483359-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07483359)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Conversion Therapy With FOLFOX-
 HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp
 3 Portal Vein Tumor Thrombus\nEstimated primary completion: June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07483359
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05366829-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT05366829)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Tislelizumab Consolidation Afte
 r Liver-Directed Therapy for Hepatocellular Carcinoma\nEstimated primary c
 ompletion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05366829
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05651022-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT05651022)
DESCRIPTION:Tislelizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Study of DECOY20 With or Without Tislelizumab in Patients With Advanced So
 lid Tumors\nEstimated primary completion: 30 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05651022
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07031700-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07031700)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: A Multicenter\, Single-Arm\, Op
 en-Label\, Phase II Trial of Mosunetuzumab in Combination With Tislelizuma
 b for r/r FL\nEstimated primary completion: 30 June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07031700
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06977828-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06977828)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Prospective\, Single-arm\, Phase II Clinical Study of Tislelizumab Combine
 d With Anlotinib and Platinum-based Doublet Perioperative Therapy for Rese
 ctable Stage II-IIIB Driver Gene-negative NSCLC\nEstimated primary complet
 ion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ti
 slelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06977828
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06877299-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06877299)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Lo
 w-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in
  Stage ⅡA-ⅢB Non-small Cell Lung Cancer\nEstimated primary completion:
  30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislel
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06877299
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07050056-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07050056)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ti
 slelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for 
 Resectable NSCLC\nEstimated primary completion: 30 June 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07050056
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07350070-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07350070)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: TACE Combined With Tislelizumab
 \, Lenvatinib\, and Carvedilol for Unresectable HCC With Cirrhotic Portal 
 Hypertension\nEstimated primary completion: 30 June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07350070
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845916-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07845916)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Qu
 ad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemoth
 erapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer\nEstimate
 d primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07845916
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07068516-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07068516)
DESCRIPTION:Tislelizumab\, phase 3\, Gastric Cancer.\nStudy: Perioperative 
 Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positiv
 e Gastric/GEJ Cancer\nEstimated primary completion: 30 June 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07068516
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03967977-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT03967977)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Study of Tislelizumab in Combin
 ation With Chemotherapy Compared to Chemotherapy Alone for Participants Wi
 th Urothelial Carcinoma\nEstimated primary completion: 30 June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03967977
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07030140-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07030140)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Phase II Study of Neoadjuvant T
 islelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresecta
 ble Hilar Cholangiocarcinoma\nEstimated primary completion: 1 July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07030140
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05189457-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT05189457)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: First Strike\, Second Strike Th
 erapies for High Risk Metastatic Castration Sensitive Prostate Cancer\nEst
 imated primary completion: 15 July 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05189457
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059299-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT07059299)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: A Phase Ib Trial Evaluating the
  Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT 
 for Resectable Esophagogastric Adenocarcinoma\nEstimated primary completio
 n: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisle
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07059299
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04501523-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT04501523)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: A Prospective\, Phase II Trial 
 Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC\nEs
 timated primary completion: August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04501523
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04271956-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT04271956)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Efficacy and Safety of Zanubrut
 inib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients 
 With Richter Transformation\nEstimated primary completion: August 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04271956
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07046221-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07046221)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Tislelizumab Combined With Chemotherapy for Resectable Esophageal Sq
 uamous Cell Carcinoma Followed by CRT or Surgery\nEstimated primary comple
 tion: 1 August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07046221
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07089199-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07089199)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ti
 slelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable
  Non-small Cell Lung Cancer : A Prospective\, Single-Arm\, Phase II Study\
 nEstimated primary completion: 10 August 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07089199
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469306-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07469306)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Short-Course RT Plus CAPOX and 
 Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rec
 tal Cancer\nEstimated primary completion: 10 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07469306
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925866-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07925866)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ti
 slelizumab Combined With Tofacitinib and Docetaxel for NSCLC After Failure
  of First-Line Immunotherapy\nEstimated primary completion: 30 August 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07925866
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05359393-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT05359393)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: A Combination Therapy Including
  Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metas
 tasis\nEstimated primary completion: 1 September 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05359393
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06560528-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06560528)
DESCRIPTION:Tislelizumab\, phase 2\, Gastric Cancer.\nStudy: Disitamab Vedo
 tin Combined With Tislelizumab and Capecitabine in the Perioperative Treat
 ment of Locally Advanced Gastric Cancer With HER2 Overexpression\nEstimate
 d primary completion: 1 September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06560528
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07888309-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270911
DTEND;VALUE=DATE:20270912
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07888309)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: SCRT + Fruquintinib + Tislelizu
 mab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for 
 Locally Advanced Low Rectal Cancer\nEstimated primary completion: 11 Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7888309
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07145931-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270920
DTEND;VALUE=DATE:20270921
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07145931)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Neoadjuvant Immunochemotherapy 
 and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell C
 arcinoma Invading the Skull Base\nEstimated primary completion: 20 Septemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071
 45931
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06233942-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT06233942)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: Phase 1a/1b First-in-Human Stud
 y of BG-C9074 Alone and in Combination With Other Anticancer Therapies in 
 Patients With Advanced Solid Tumors\nEstimated primary completion: 28 Sept
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06233942
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07317609-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT07317609)
DESCRIPTION:Tislelizumab\, phase 1\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With 
 Endoscopic Resection for Esophageal Cancer (Endosurgery-02)\nEstimated pri
 mary completion: 30 September 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07317609
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908733-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06908733)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: In
 tegrating Surgery and Radiotherapy Following Tislelizumab-based Conversion
  Therapy in N3-Stage III NSCLC\nEstimated primary completion: 30 September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06908
 733
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132008-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07132008)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Neoadjuvant CAPOX Plus Tisleliz
 umab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer\nEstimated pr
 imary completion: 30 September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07132008
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07147426-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271020
DTEND;VALUE=DATE:20271021
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07147426)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Tislelizumab Combined With Chem
 otherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced 
 Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)\nEstima
 ted primary completion: 20 October 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07147426
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07043400-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07043400)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: A Study to Investigate Tisleliz
 umab Administered as Subcutaneous Injection Versus Intravenous Infusion Pl
 us Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gas
 troesophageal Junction Adenocarcinoma\nEstimated primary completion: 30 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07043400
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06520683-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06520683)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Adjuvant PD-1 Blockade for High
 -risk Stage-II DMMR/MSI-H Colorectal Cancer\nEstimated primary completion:
  1 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tis
 lelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06520683
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243691-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Tislelizumab: Phase na readout est. (NCT07243691)
DESCRIPTION:Tislelizumab\, phase na.\nStudy: Study on the Therapeutic Effec
 t of Different Infusion Times of Tislelizumab on Postoperative High-risk H
 epatocellular Carcinoma\nEstimated primary completion: 1 November 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07243691
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07453875-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT07453875)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: LDRT Sequential NIPS Immunochem
 otherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer\nEstim
 ated primary completion: 30 November 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07453875
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07231575-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07231575)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ne
 oadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resecta
 ble EGFR Wild-type NSCLC\nEstimated primary completion: 30 November 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07231575
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05547321-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT05547321)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: Efficacy and Safety Study of OM
 TX705\, Monotherapy and Anti-PD-1-combined\, in Subjects With Advanced Sol
 id Tumors.\nEstimated primary completion: December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05547321
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389187-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT07389187)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: Safety and Preliminary Efficacy
  Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic C
 astration-Resistant Prostate Cancer (mCRPC)\nEstimated primary completion:
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisle
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07389187
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07561060-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT07561060)
DESCRIPTION:Tislelizumab\, phase 1/2.\nStudy: Low Rectal Cancer Treated Wit
 h Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy\nEs
 timated primary completion: December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07561060
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431270-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT05431270)
DESCRIPTION:Tislelizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Dose Escalation/Expansion Study of Mavrostobart (PT199)\, an Anti-CD73 mAb
 \, Administered Alone and in Combination With a PD-1 Inhibitor or Chemothe
 rapy (the MORNINGSTAR Study)\nEstimated primary completion: December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05431270
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846358-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT07846358)
DESCRIPTION:Tislelizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 This is a Multicenter\, Open-label\, Phase I/II Study to Explore the Safet
 y\, Tolerability\, Pharmacokinetics (PK)\, and Preliminary Efficacy of GFH
 276 in Patients With Advanced NSCLC Harboring a RAS Mutation.\nEstimated p
 rimary completion: December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07846358
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05604560-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT05604560)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: A Neoadjuvant Study of Tisleliz
 umab and SX-682 for Resectable Pancreas Cancer\nEstimated primary completi
 on: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ti
 slelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05604560
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07296705-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07296705)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Neoadjuvant Zanidatamab + Tisle
 lizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive
  MIBC\nEstimated primary completion: December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07296705
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764355-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06764355)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Sur
 gery for Advanced Esophageal Squamous Cell Carcinoma\nEstimated primary co
 mpletion: December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06764355
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07099547-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07099547)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Study of ZG005 in Combination W
 ith Platinum-Based Chemotherapy in Participants With Advanced Biliary Trac
 t Carcinoma\nEstimated primary completion: December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07099547
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132463-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07132463)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Neoadjuvant Chemoradiotherapy F
 ollowed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-
 low Rectal Cancer: The RELIEVE-02 Study\nEstimated primary completion: Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07132463
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136077-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07136077)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: A Phase 2 Trial of Fruquintinib
  and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal 
 Cancer After Completion of Adjuvant Chemotherapy\nEstimated primary comple
 tion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07136077
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085182-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271210
DTEND;VALUE=DATE:20271211
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07085182)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ti
 slelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Ce
 ll Lung Cancer：A Prospective\, Single-Arm\, Phase II Study\nEstimated pr
 imary completion: 10 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07085182
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669415-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07669415)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: A Study of LM-168 Combined With
  Other Anti-tumor Treatments in Participants With Advanced Solid Tumors\nE
 stimated primary completion: 15 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07669415
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502768-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT07502768)
DESCRIPTION:Tislelizumab\, phase 1/2.\nStudy: Tislelizumab Plus Zeprumetost
 at for Relapsed or Refractory NK/T-Cell Lymphoma\nEstimated primary comple
 tion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07502768
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06258811-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06258811)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Neoadjuvant Immunochemotherapy 
 for LAOSCC\nEstimated primary completion: 30 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06258811
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07480382-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Tislelizumab: Phase na readout est. (NCT07480382)
DESCRIPTION:Tislelizumab\, phase na.\nStudy: Safety and Efficacy of LVD + C
 -TACE + Tis/Len for Unresectable Right-Liver HCC\nEstimated primary comple
 tion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07480382
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07077369-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT07077369)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: WGc-0201 Plus Tislelizumab in H
 CC With High Risk of Recurrence and Metastasis After Radical Therapy\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07077369
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Study of Precision Treatment fo
 r Rare Tumours in China Guided by PDO and NGS\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06692491
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764251-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06764251)
DESCRIPTION:Tislelizumab\, phase 2\, Gastric Cancer.\nStudy: Tislelizumab C
 ombined with SOX Regimen in the Treatment of Locally Advanced Gastric Canc
 er/gastroesophageal Junction Adenocarcinoma\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ti
 slelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06764251
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06781112-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06781112)
DESCRIPTION:Tislelizumab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: A Ph
 ase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Adva
 nced Nasopharyngeal Carcinoma\nEstimated primary completion: 31 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0678111
 2
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849986-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06849986)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: IO Combined With AI as First-li
 ne Treatment for Patients With Soft Tissue Sarcoma(TAIS)\nEstimated primar
 y completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06849986
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07370337-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07370337)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Induction Chemotherapy Combined
  With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the Ext
 ernal Auditory Canal\nEstimated primary completion: 31 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07370337
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418190-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07418190)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Efficacy and Safety of Zanubrut
 inib\, Rituximab\, and Lenalidomide (ZR²) in Combination With Tislelizuma
 b for Relapsed/Refractory Follicular Lymphoma\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07418190
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07425795-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07425795)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Tislel
 izumab Combined With Chemotherapy Followed by Thoracic Consolidation Radio
 therapy in the First-line Treatment of Extensive Stage Small Cell Lung Can
 cer\nEstimated primary completion: 31 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07425795
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528274-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07528274)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Mi
 crowave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After F
 irst-Line Immunotherapy Failure\nEstimated primary completion: 31 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07528
 274
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07584733-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07584733)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Biomarker-Enriched Kidney-Prese
 rving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive H
 igh-Risk Upper Tract Urothelial Carcinoma\nEstimated primary completion: 3
 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisl
 elizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07584733
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07721103-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07721103)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Early Response-guided Sequential Radiotherapy After Chemoimmunothera
 py for Locally Advanced Esophageal Squamous Cell Carcinoma\nEstimated prim
 ary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07721103
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06673693-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06673693)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Tislelizumab Combined With SBRT
  for the Treatment of Head and Neck Squamous Cell Carcinoma\nEstimated pri
 mary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06673693
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811752-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07811752)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Sacituzumab Govitecan Combined With Tislelizumab for Locally Advance
 d/Metastatic Esophageal Cancer\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078117
 52
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07331428-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07331428)
DESCRIPTION:Tislelizumab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: MRG0
 03 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent N
 PC\nEstimated primary completion: 31 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07331428
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07068542-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase na readout est. (NCT07068542)
DESCRIPTION:Tislelizumab\, phase na.\nStudy: Sacituzumab Tirumotecan Combin
 ed With Immunotherapy in Advanced Thyroid Cancer\nEstimated primary comple
 tion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07068542
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05526924-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT05526924)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: Dosing Study of Radiation Combi
 ned With Tislelizumab and Pamiparib in Patients With Previously Treated He
 ad and Neck Cancer\nEstimated primary completion: 1 January 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05526924
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678580-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07678580)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemothe
 rapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma\nE
 stimated primary completion: 31 January 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07678580
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463248-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07463248)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: PULSAR Combined With Fecal Micr
 obiota Transplantation for Advanced Hepatocellular Carcinoma Progressing A
 fter First-Line Targeted-Immunotherapy\nEstimated primary completion: 31 J
 anuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisleliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07463248
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388758-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07388758)
DESCRIPTION:Tislelizumab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Scip
 ibaimab Combined With Tislelizumab in Patients With First-Line Treatment-F
 ailed Recurrent/Metastatic Nasopharyngeal Carcinoma\nEstimated primary com
 pletion: February 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07388758
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733180-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07733180)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: A Study Investigating Alternate Schedules of Tislelizumab Plus Chemo
 therapy in Japanese Patients With First-line Advanced ESCC\nEstimated prim
 ary completion: 28 February 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07733180
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06541639-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT06541639)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: EVM16 Injection as a Single and
  Combination With Tislelizumab in Solid Tumors\nEstimated primary completi
 on: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisle
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06541639
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06722183-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06722183)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Futibatinib in Combination With
  (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities\
 nEstimated primary completion: March 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06722183
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363512-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07363512)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Efficacy and Safety of Radiothe
 rapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatoce
 llular Carcinoma Complicated With Portal Vein Tumor Thrombus\nEstimated pr
 imary completion: March 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07363512
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05502250-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT05502250)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Tislelizumab\, Gemcitabine and 
 Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation 
 in Patients in Metabolic Complete Remission\nEstimated primary completion:
  March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisleliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05502250
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06871527-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT06871527)
DESCRIPTION:Tislelizumab\, phase 1/2\, Gastric Cancer.\nStudy: Fruquintinib
  Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advan
 ced Gastric Cancer\nEstimated primary completion: 30 March 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06871527
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06349837-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT06349837)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: Safety and Tolerability of LDRT
  Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumo
 rs\nEstimated primary completion: 31 March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06349837
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109401-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07109401)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Periop
 erative Immunotherapy for Resectable Limited-Stage SCLC\nEstimated primary
  completion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07109401
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244705-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT07244705)
DESCRIPTION:Tislelizumab\, phase 1/2.\nStudy: A Study of ABT-301 Plus Tisle
 lizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC\nEstim
 ated primary completion: April 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07244705
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07058103-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07058103)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Tislelizumab \, Cyclophosphamid
 e\, Mitoxantrone Liposomes\, Chidamide\, and Prednisone in the Treatment o
 f R/R AITL\nEstimated primary completion: 1 April 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07058103
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793917-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06793917)
DESCRIPTION:Tislelizumab\, phase 3\, Gastric Cancer.\nStudy: Tislelizumab P
 lus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter\
 , Open-label\, Randomized Phase III Studyunresectable or Metastatic Gastri
 c/Gastroesophageal Junction Adenocarcinoma\nEstimated primary completion: 
 1 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisleli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06793917
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07569068-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07569068)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Neoadjuvant Tislelizumab + LM-3
 02 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarc
 inoma\nEstimated primary completion: 30 April 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07569068
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601737-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07601737)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Nimotuzumab Combined With Immun
 otherapy and Chemotherapy in the Treatment of Locally Advanced Head and Ne
 ck Squamous Cell Carcinoma\nEstimated primary completion: 30 April 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07601737
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07373990-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07373990)
DESCRIPTION:Tislelizumab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Shor
 t-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal C
 arcinoma\nEstimated primary completion: 30 April 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07373990
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06944496-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06944496)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: A Study of Disitamab Vedotin Co
 mbined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined Wit
 h Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction A
 denocarcinoma\nEstimated primary completion: 15 May 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06944496
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671339-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT07671339)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: A Study of ELI-002 7P\, With or
  Without Tislelizumab\, in People With Pancreatic Cancer\nEstimated primar
 y completion: June 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07671339
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685704-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07685704)
DESCRIPTION:Tislelizumab\, phase 2\, Gastric Cancer.\nStudy: Zanidatamab Co
 mbined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positi
 ve (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenoc
 arcinoma: a Phase II Open-Label Study\nEstimated primary completion: June 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076857
 04
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07290985-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07290985)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: AACR Adaptive Biomarker-Driven 
 Organ Preservation Trial in Gastroesophageal Adenocarcinomas\nEstimated pr
 imary completion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07290985
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868732-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT06868732)
DESCRIPTION:Tislelizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Ev
 aluation of JSKN016 Combination Therapy in Subjects With NSCLC\nEstimated 
 primary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06868732
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047586-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07047586)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Lenvatinib Plus Tislelizumab Ve
 rsus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With 
 Anti-PD1/PD-L1 and Bevacizumab\nEstimated primary completion: 30 June 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07047586
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609667-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07609667)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: SKB315 in Combination Therapy i
 n Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma\nEstimated p
 rimary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07609667
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06529523-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06529523)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Tislelizumab in People With Col
 orectal Cancer\nEstimated primary completion: July 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06529523
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06965829-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06965829)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: The Effect of Neoadjuvant Chemo
 immnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC\nEstimat
 ed primary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06965829
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07655661-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07655661)
DESCRIPTION:Tislelizumab\, phase 2\, Gastric Cancer.\nStudy: Mannatide Comb
 ined With CAPOX and Tislelizumab for Advanced Gastric Cancer.\nEstimated p
 rimary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07655661
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356675-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Tislelizumab: Phase 4 readout est. (NCT06356675)
DESCRIPTION:Tislelizumab\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: A 
 Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients
  With Advanced NSCLC With Driver-negative After Progression to Immunothera
 py\nEstimated primary completion: 1 July 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06356675
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06596473-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280723
DTEND;VALUE=DATE:20280724
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT06596473)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: A Study of BG-C477 in Participa
 nts With Advanced Solid Tumors\nEstimated primary completion: 23 July 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06596473
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686926-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07686926)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Adva
 nced Esophageal Squamous Cell Carcinoma\, Phase II\nEstimated primary comp
 letion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07686926
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07681297-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT07681297)
DESCRIPTION:Tislelizumab\, phase 1/2.\nStudy: Tislelizumab in Combination W
 ith Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation 
 in Immunotherapy-Resistant and Central Nervous System Disease\nEstimated p
 rimary completion: August 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07681297
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07168317-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07168317)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Tislelizumab \, Cyclophosphamid
 e\, Mitoxantrone Liposomes\, Chidamide\, and Prednisone in the Treatment o
 f New Diagnosed AITL\nEstimated primary completion: 1 August 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07168317
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745908-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06745908)
DESCRIPTION:Tislelizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Cl
 inical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint 
 Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With 
 Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resist
 ance to Immune Checkpoint Inhibitor Therapy\nEstimated primary completion:
  September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisl
 elizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06745908
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614231-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280908
DTEND;VALUE=DATE:20280909
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06614231)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ne
 oajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectabl
 e Stage IIIA/N2 Non-small Cell Lung Cancer\nEstimated primary completion: 
 8 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tis
 lelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06614231
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07842276-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280920
DTEND;VALUE=DATE:20280921
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07842276)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Utidelone Capsules Combined Wit
 h Doxorubicin for Advanced Soft Tissue Sarcoma\nEstimated primary completi
 on: 20 September 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07842276
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07746141-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT07746141)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: A First-in-Human Study Investig
 ating BG-85738 Alone or in Combination With Other Antitumor Agents in Pati
 ents With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS)
  Mutations\nEstimated primary completion: 30 September 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07746141
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06093061-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06093061)
DESCRIPTION:Tislelizumab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Tisl
 elizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregio
 nally-advanced Nasopharyngeal Carcinoma\nEstimated primary completion: Oct
 ober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6093061
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582265-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT05582265)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Tislelizumab Combined With Chem
 otherapy Followed by Surgery Versus Up-front Surgery in Resectable Head an
 d Neck Squamous Cell Carcinoma (REDUCTION-I)\nEstimated primary completion
 : October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisle
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05582265
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07385703-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07385703)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Clinical Study on the Efficacy 
 and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab
  Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Ju
 nction Adenocarcinoma.\nEstimated primary completion: October 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07385703
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07842887-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT07842887)
DESCRIPTION:Tislelizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third
 -Generation EGFR-TKI Resistance\nEstimated primary completion: 1 October 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0784288
 7
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05627115-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT05627115)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Response Adapted Incorporation 
 of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgk
 in lYmphoma\nEstimated primary completion: 1 October 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05627115
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432984-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07432984)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Fe
 cal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced o
 r Metastatic NSCLC\nEstimated primary completion: 30 October 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07432984
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07561983-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07561983)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ti
 slelizumab Plus Chemotherapy and BACE for Unresectable NSCLC\nEstimated pr
 imary completion: 31 October 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07561983
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812467-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07812467)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Rimegepant-Sensitized Neoadjuva
 nt Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma\nE
 stimated primary completion: 31 October 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07812467
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07131319-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Tislelizumab: Phase 2/3 readout est. (NCT07131319)
DESCRIPTION:Tislelizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: 
 SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC\n
 Estimated primary completion: 31 October 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07131319
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05977673-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT05977673)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Efficacy and Safety of Frontlin
 e Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for St
 andard Frontline Chemotherapy\nEstimated primary completion: November 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05977673
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06876688-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06876688)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Relma-cel Followed by Tislelizu
 mab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma\nEs
 timated primary completion: 30 November 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06876688
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128693-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07128693)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: A Single-center\, Multicohort\, Phase II Clinical Study Evaluating t
 he Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresec
 table\, Locally Advanced\, Recurrent\, or Metastatic Esophageal Squamous C
 ell Carcinoma\nEstimated primary completion: December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07128693
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554456-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tislelizumab: Phase 2/3 readout est. (NCT07554456)
DESCRIPTION:Tislelizumab\, phase 2/3\, Esophageal Squamous Cell Carcinoma.\
 nStudy: A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluoroura
 cil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Tre
 atment in Patients With Unresectable\, Locally Advanced Recurrent or Metas
 tatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07554456
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07485920-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281210
DTEND;VALUE=DATE:20281211
SUMMARY:Tislelizumab: Phase 4 readout est. (NCT07485920)
DESCRIPTION:Tislelizumab\, phase 4\, Small Cell Lung Cancer.\nStudy: A Pros
 pective\, Multicenter Exploratory Clinical Study on Consolidation Therapy 
 With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lu
 ng Cancer\nEstimated primary completion: 10 December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07485920
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518706-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07518706)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Neoadjuvant Tislelizumab-Lenvat
 inib vs Surgery Alone in Stage Ia HCC With Narrow Margin\nEstimated primar
 y completion: 30 December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07518706
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07353294-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT07353294)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: Propranolol With Tislelizumab P
 lus GC in Neoadjuvant Bladder UC\nEstimated primary completion: 31 Decembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0735
 3294
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07694765-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT07694765)
DESCRIPTION:Tislelizumab\, phase 1/2.\nStudy: A Study of LM-364 as a Single
  Agent or in Combination With Anti-tumor Therapy in Patients With Advanced
  Solid Tumors\nEstimated primary completion: 31 December 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07694765
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196540-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07196540)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: IP rmhTNF-NC + Tislelizumab + P
 alliat RT for GIT Tumor Malignant Ascites After Failed Std Tx\nEstimated p
 rimary completion: 31 December 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07196540
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07039162-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07039162)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Study of Tislelizumab Combined With Chemoradiotherapy and Surgery fo
 r Unresectable Esophageal Squamous Cell Carcinoma\nEstimated primary compl
 etion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07039162
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07815223-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07815223)
DESCRIPTION:Tislelizumab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Phas
 e II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradioth
 erapy in LS-SCLC\nEstimated primary completion: 31 December 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07815223
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700667-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07700667)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: SKB500 Combinations in Patients With Esophageal Squamous Cell Carcin
 oma\nEstimated primary completion: 31 December 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07700667
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07790419-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tislelizumab: Phase 4 readout est. (NCT07790419)
DESCRIPTION:Tislelizumab\, phase 4.\nStudy: A Prospective\, Single-Arm\, Op
 en-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Inf
 usion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in 
 Patients With Postoperative Hepatocellular Carcinoma and Microvascular Inv
 asion\nEstimated primary completion: 31 December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07790419
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07328009-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07328009)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: A Platform Trial for Personaliz
 ed and Adaptive Therapies in Hepatocellular Carcinoma\nEstimated primary c
 ompletion: 15 January 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07328009
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07408609-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290220
DTEND;VALUE=DATE:20290221
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07408609)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Perioperative Chemotherapy With
  Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Ga
 stroesophageal Junction Adenocarcinoma\nEstimated primary completion: 20 F
 ebruary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisleli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07408609
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05981703-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT05981703)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: A Study Investigating BGB-26808
  Alone or in Combination With Tislelizumab in Participants With Advanced S
 olid Tumors\nEstimated primary completion: 28 February 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05981703
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07377045-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT07377045)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: Clinical Trial of OMTX705 in Co
 mbination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients Wit
 h Advanced/Metastatic Pancreatic Adenocarcinoma\nEstimated primary complet
 ion: March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisl
 elizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07377045
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06323369-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290325
DTEND;VALUE=DATE:20290326
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06323369)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Tislelizumab Combined With Chem
 otherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinica
 lly Node-negative Head and Neck Squamous Cell Carcinoma\nEstimated primary
  completion: 25 March 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06323369
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06167785-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06167785)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: A Study to Evaluate Zanubrutini
 b and Tislelizumab in Progressive Lymphoma Post CAR-T\nEstimated primary c
 ompletion: April 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06167785
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06332274-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06332274)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: tislelizUMaB in canceR Patients
  With molEcuLar residuaL Disease\nEstimated primary completion: April 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06332274
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07414836-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT07414836)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: A First-in-Human Study of BG-C0
 979 in Adults With Advanced Solid Tumors\nEstimated primary completion: 30
  April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisleliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07414836
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06957938-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06957938)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Comparing Neoadjuvant Chemother
 apy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locall
 y Advanced Laryngeal and Hypopharyngeal Carcinoma\nEstimated primary compl
 etion: 1 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ti
 slelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06957938
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609121-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07609121)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Hy
 pofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unr
 esectable Stage III NSCLC\nEstimated primary completion: 31 May 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07609121
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729670-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07729670)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Mu
 ltimodal Ablation Combined With Perioperative Tislelizumab and Chemotherap
 y for Resectable II-IIIB NSCLC\nEstimated primary completion: June 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07729670
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744698-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tislelizumab: Phase 4 readout est. (NCT07744698)
DESCRIPTION:Tislelizumab\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: Me
 tronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advance
 d Lung Cancer (PULSE Study)\nEstimated primary completion: June 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07744698
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07468071-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290611
DTEND;VALUE=DATE:20290612
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT07468071)
DESCRIPTION:Tislelizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Rollover Study for Participants Who Have Been Treated With and Are Continu
 ing to Benefit From Opnurasib as a Single Agent or in Combination With Oth
 er Study Treatments\nEstimated primary completion: 11 June 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07468071
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07315750-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07315750)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: A Study of Disitamab Vedotin Co
 mbined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With
  Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advance
 d Gastric or Gastroesophageal Junction Adenocarcinoma.\nEstimated primary 
 completion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07315750
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07248696-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tislelizumab: Phase na readout est. (NCT07248696)
DESCRIPTION:Tislelizumab\, phase na\, Nasopharyngeal Carcinoma.\nStudy: Tis
 lelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo
  Metastatic Nasopharyngeal Carcinoma: A Prospective\, Phase II Trial\nEsti
 mated primary completion: 30 June 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07248696
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729592-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07729592)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Dapagliflozin Add-on in Unresec
 table HCC With Metabolic Syndrome\nEstimated primary completion: July 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07729592
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07086456-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290719
DTEND;VALUE=DATE:20290720
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07086456)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Co
 mbination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizuma
 b in Patients With Locally Advanced Non-Small Cell Lung Cancer\nEstimated 
 primary completion: 19 July 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07086456
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940388-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06940388)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Total Neoadjuvant Treatment Wit
 h or Without Tislelizumab for Locally Advanced Rectal Cancer.\nEstimated p
 rimary completion: August 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06940388
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07120282-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07120282)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-R
 isk Stage I NSCLC\nEstimated primary completion: 15 August 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07120282
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07763171-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07763171)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Paclitaxel\, Ramucirumab and Ti
 slelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Scor
 e of 5 or More Advanced Gastroesophageal Adenocarcinoma\nEstimated primary
  completion: September 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07763171
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07205731-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07205731)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Phase II Study Evaluating Safety and Efficacy of Tislelizumab for El
 derly Patients Unfit for Chemotherapy\, With Advanced Esophageal Squamous-
 cell Carcinoma\nEstimated primary completion: October 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07205731
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563245-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20291115
DTEND;VALUE=DATE:20291116
SUMMARY:Tislelizumab: Phase 2/3 readout est. (NCT06563245)
DESCRIPTION:Tislelizumab\, phase 2/3.\nStudy: Brentuximab Vedotin for Newly
  Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment\nEstimated prima
 ry completion: 15 November 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06563245
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776340-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07776340)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Induction PD-1 Inhibitor and Ch
 emotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV
 -negative LA-HNSCC\nEstimated primary completion: December 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07776340
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07557914-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07557914)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Epalrestat Combined With HAIC\,
  Donafenib and Tislelizumab as First-line Treatment for Patients With Unre
 sectable HCC and Diabetes\nEstimated primary completion: December 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07557914
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502300-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07502300)
DESCRIPTION:Tislelizumab\, phase 3\, Small Cell Lung Cancer.\nStudy: A Stud
 y Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing
  Chemotherapy Combined With Tislelizumab as First-line Treatment in Patien
 ts With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)\nEstimated pr
 imary completion: December 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07502300
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341360-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tislelizumab: Phase 1 readout est. (NCT07341360)
DESCRIPTION:Tislelizumab\, phase 1.\nStudy: Pseudovax - A Cancer Vaccine fo
 r Patients With Pseudomyxoma Peritonei\nEstimated primary completion: 31 D
 ecember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisleli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07341360
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06856837-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06856837)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: - IKF/AIO-QUINTIS - Evaluating 
 Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / P
 roficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without 
 Active Liver Metastases\nEstimated primary completion: 31 December 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06856837
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691515-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07691515)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Intraarterial Therapies Plus Ti
 slelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin 
 in Unresectable Intrahepatic Cholangiocarcinoma\nEstimated primary complet
 ion: January 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ti
 slelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07691515
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07475026-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07475026)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: A Study of Neoadjuvant Tisleliz
 umab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence\nEstimat
 ed primary completion: 31 January 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07475026
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775040-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07775040)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Sp
 atially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for B
 ulky Stage III NSCLC: A Phase II Trial\nEstimated primary completion: 30 J
 une 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 775040
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06903273-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06903273)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: Neoadjuvant Tislelizumab\, Gemc
 itabine\, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma\nE
 stimated primary completion: 1 July 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06903273
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847905-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20301019
DTEND;VALUE=DATE:20301020
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT07847905)
DESCRIPTION:Tislelizumab\, phase 1/2.\nStudy: A Phase I/II of LM-364 as a S
 ingle Agent or in Combination With Anti-tumor Therapy in Patients With Adv
 anced Solid Tumors\nEstimated primary completion: 19 October 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07847905
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271992-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20301214
DTEND;VALUE=DATE:20301215
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07271992)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: TREND-02 - a Phase II Explorato
 ry De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizu
 mab (SG/I) in Early Triple-negative Breast Cancer\nEstimated primary compl
 etion: 14 December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07271992
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06914011-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20310628
DTEND;VALUE=DATE:20310629
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06914011)
DESCRIPTION:Tislelizumab\, phase 3\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Res
 ected Locally Advanced Esophageal Squamous Cell Carcinoma\nEstimated prima
 ry completion: 28 June 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06914011
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05934331-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20310806
DTEND;VALUE=DATE:20310807
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT05934331)
DESCRIPTION:Tislelizumab\, phase 2.\nStudy: A LM-302 Combination With Other
  Anti-Tumor Therapies Phase ll Study\nEstimated primary completion: 6 Augu
 st 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT059
 34331
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07715396-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20311030
DTEND;VALUE=DATE:20311031
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07715396)
DESCRIPTION:Tislelizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ad
 dition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metasta
 tic Non-small Cell Lung Cancer With a High Tumor Burden\nEstimated primary
  completion: 30 October 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07715396
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900061-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07900061)
DESCRIPTION:Tislelizumab\, phase 3.\nStudy: Modified Short-Course Radiother
 apy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer\nEstim
 ated primary completion: December 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07900061
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554521-2010@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07554521)
DESCRIPTION:Tislelizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nS
 tudy: A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemoth
 erapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroeso
 phageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial an
 d Ethnic Minority Patients in the United States\nEstimated primary complet
 ion: 31 December 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tislelizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07554521
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
